Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
US7417070 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2026
(2 years from now) | |
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9422223 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
US9278901 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
US8252839 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
US7544713 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2024
(3 months from now) | |
US9393203 | UNITED THERAP | Osmotic drug delivery system |
Apr, 2026
(2 years from now) | |
US8410169 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Feb, 2030
(5 years from now) | |
US8349892 | UNITED THERAP | Solid formulations of prostacyclin analogs |
Jan, 2031
(6 years from now) | |
US8747897 | UNITED THERAP | Osmotic drug delivery system |
Aug, 2031
(7 years from now) |
Orenitram is owned by United Therap.
Orenitram contains Treprostinil Diolamine.
Orenitram has a total of 14 drug patents out of which 0 drug patents have expired.
Orenitram was authorised for market use on 20 December, 2013.
Orenitram is available in tablet, extended release;oral dosage forms.
Orenitram can be used as use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1)., method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil, a method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; a method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form.
The generics of Orenitram are possible to be released after 11 August, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically accept...
Dosage: TABLET, EXTENDED RELEASE;ORAL